The biggest 10x latent unlock is turning prediction abundance into downstream work.

The most underexploited AI asset right now is not a chat surface. It is the enormous pile of machine-readable scientific predictions that already exists, plus enough local compute to interrogate it privately, plus national compute programs that can put the same loop in the hands of students, startups, and public-interest teams. The missing product is the translator between prediction abundance and downstream work.

The thesis:

AlphaFold made structure cheap. GB10-class Blackwell desktops make local reasoning and batch triage cheap. India-style shared compute makes access cheaper. The 10x comes from combining those three into an experiment router: read the predicted structure, read the confidence, read the surrounding literature, rank the next test, and hand a human a work order worth running.

Prediction is not the product

AlphaFold DB provides open access to over 200 million protein structure predictions. DeepMind says AlphaFold has been used by more than 3 million researchers across more than 190 countries, and that the database has helped move biology into an era of structural abundance. That is the obvious miracle. The less obvious opportunity is that most organizations are still treating the abundance like a reference shelf.

A reference shelf helps a careful scientist. A 10x tool changes the queue. It asks: which predicted structures are worth buying reagents for, which pockets are likely spurious, which domains are confidently placed, which literature claims are now testable, which abandoned datasets should be reopened, and which five experiments should run before the team burns a month on the wrong target?

That is the unlock: move from "we can look up a structure" to "we can continuously price the next unit of experimental work." The value is not the prediction. The value is a better experimental backlog.

The confidence scores are the product surface

The dangerous version of this idea treats AlphaFold output as if it were truth. The useful version treats AlphaFold output as a ranked map of where to think harder. EMBL-EBI's training material is clear about the two signals an operator must respect: pLDDT measures local confidence residue by residue, while PAE measures confidence in the relative placement of residues and domains.

That distinction is the start of the operating system. High local confidence can make a binding-site hypothesis worth inspecting. High PAE between domains can warn you not to overinterpret their relative orientation. A low-confidence region can be disorder, missing context, or a prompt for a different experimental method. The product should not hide that uncertainty. It should turn uncertainty into routing.

Rank the target

Pull AlphaFold DB structures, confidence scores, sequence annotations, literature, pathway context, patents, and available assays into one scorecard.

Rank the next experiment

Convert the scorecard into a small list of tests: expression, mutagenesis, docking follow-up, variant interpretation, purification, or a field-relevant assay.

Rank the cost of being wrong

Put uncertainty in the foreground. A bad domain orientation should be cheaper to falsify than a month of confident storytelling.

Rank the public value

Prefer neglected targets where a useful prediction-to-test packet helps agriculture, antimicrobial resistance, rare disease research, or local manufacturing.

Your GB10 is a desk-side hypothesis factory

NVIDIA's DGX Spark page describes a GB10 Grace Blackwell system with up to 1 petaflop of FP4 AI performance, 128 GB of coherent unified memory, and support for local inference on models up to 200 billion parameters. NVIDIA's launch note frames it as a compact desktop system for local agents, model testing, fine-tuning, and data-science workflows. That does not make it a wet lab. It makes it the night shift before the wet lab.

The GB10-class move is to run the boring but expensive thinking locally: parse thousands of AlphaFold structures, generate per-target uncertainty summaries, compare protein families, pre-rank assay candidates, draft protocols, read open papers, and produce a falsifiable work packet before anyone orders material. It is not replacing the bench. It is protecting the bench from low-quality work.

This is exactly where local compute matters. The sensitive part is often not one magic prompt. It is the messy pre-work: half-formed target lists, unpublished lab intuition, grant ideas, supply constraints, failure notes, and local disease or crop context. A local box lets the operator rehearse that reasoning without turning every early hypothesis into a cloud artifact.

How Jensen, Garry, and Modi would each pressure-test it

Treat these as operating lenses, not endorsements.

Lens	Question	Product implication
Jensen Huang	Where is the AI factory?	Build a pipeline, not a demo: ingest predictions, run local agents, cache embeddings, score uncertainty, emit work orders, and send the best jobs to larger compute only when needed.
Garry Tan	Who wants this badly enough this week?	Start with a painful wedge: one crop lab, one protein engineering team, one neglected-disease group, one biotech services firm that already spends money deciding what to test next.
Narendra Modi	How does this become capability for millions, not only elite labs?	Package the loop for affordable shared compute, regional priorities, skilling, local languages, and public-good challenges where better triage has national leverage.

The three views converge. Jensen says: make compute productive. Garry says: find the customer whose pain is immediate. Modi says: make the capability broad enough to matter at population scale. The shared answer is not "build a biology chatbot." The shared answer is "build the prediction-to-work operating layer."

The India angle is not abstract

The IndiaAI Mission was approved with a budget outlay of INR 10,371.92 crore to make AI in India and make AI work for India. Current government releases say more than 38,000 GPUs have been onboarded for a common compute facility serving startups and academia at subsidized rates. Prime Minister Modi's 2026 AI Impact Summit address framed the future of work as humans and intelligent systems co-creating, co-working, and co-evolving.

That infrastructure becomes much more interesting when attached to concrete scientific queues. Agricultural pests. Low-pesticide farming. Enzyme discovery. Antimicrobial resistance. Variant interpretation. Public labs that need better prioritization more than they need prettier dashboards. Shared compute becomes strategic when it turns open predictions into local action.

Seven immediate wedges

AlphaFold-to-assay router: given a target list, output the top experiments, confidence caveats, supply needs, and expected failure modes.
Crop protein triage: rank plant and pest proteins where structure suggests a lower-pesticide intervention worth testing.
Variant consequence workbench: combine predicted structure, conservation, local confidence, known variants, and literature into an evidence packet for expert review.
Wet-lab negative-result memory: turn failed protocols into searchable constraints so the model stops proposing experiments the lab already knows are dead ends.
Public target bounties: let government, universities, and startups publish ranked public-good target lists with reproducible source trails.
Local language science operator: translate the prediction-to-test packet into the language and procedural style of the technician who will run it.
GB10 night shift: run overnight triage locally, produce ten falsifiable work packets by morning, and escalate only the expensive winners.

The first build should be embarrassingly concrete

Do not start by promising automated discovery. Start with one organism, one disease or crop context, and one kind of downstream action. Pick 100 targets. For each target, fetch structure predictions, pLDDT, PAE, sequence annotations, available papers, known assays, procurement friction, and a human-readable uncertainty note. Then force the system to produce only three outputs.

A ranked top-10 list of targets worth human review.
A one-page work packet for each target with the confidence caveats visible.
A falsification plan that says what result would kill the hypothesis quickly.

That is the first sellable artifact. Not a chat transcript. Not a cinematic demo. A ranked backlog that saves expert time and reduces bad experiments. If it cannot improve the next meeting where a team decides what to test, it is not yet a product.

The 10x is cycle compression

The plausible 10x is not that AlphaFold is always right. It is that a team can stop spending ten slow cycles assembling context before they even know what to falsify. The system can pre-read the prediction, pre-read the caveat, pre-read the literature, pre-read the local constraint, and hand the expert a smaller decision.

That changes the unit economics of curiosity. More targets can be screened. More neglected areas can be explored. More students can participate. More local problems can be translated into testable biology. The expert still decides. The bench still proves. But the queue gets sharper.

Reader move

If you have a GB10-class Blackwell box, make the first artifact tonight: choose 25 proteins from a real domain you care about, pull their AlphaFold entries, compute a confidence-aware summary, attach three papers per target, and ask the model to rank the next test with a visible reason to reject its own answer. The output should be a table a domain expert can mark up in ten minutes.

I cooked the first public version as a Disease Hypothesis Engine: it picks sickle cell disease as the initial wedge, then exposes the causal map, target ranking, repurposing queue, biomarkers, protocols, contradictions, and falsifiers in one inspectable workbench.

The frontier is not "AI can predict the structure." That part already happened. The frontier is whether you can make prediction abundance operational enough that the next experiment is better by breakfast.